Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 5/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14431980 | 1.00 | NCF1 (0.38) | NCF1DPP4DPP8DPP9DPP7 | |
| SCHEMBL23114339 | 0.90 | SHBG (0.35) | NCF1SLC6A3SHBG | |
| SCHEMBL14652454 | 0.90 | SHBG (0.35) | NCF1SLC6A3SHBG | |
| SCHEMBL25091220 | 0.88 | NCF1 (0.39) | NCF1SLC6A3 | |
| SCHEMBL19534541 | 0.86 | NCF1 (0.41) | NCF1SHBG | |
| SCHEMBL13600026 | 0.86 | NCF1 (0.41) | NCF1SHBG | |
| SCHEMBL22680846 | 0.84 | NCF1 (0.37) | NCF1SLC6A3 | |
| SCHEMBL23714265 | 0.84 | NCF1 (0.37) | NCF1SLC6A3 | |
| SCHEMBL22400186 | 0.84 | NCF1 (0.37) | NCF1SLC6A3 | |
| SCHEMBL13600012 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | NCF1 3036/4885DPP4 898/4885DPP8 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.